Clinical Scorecard: Investigating the relationship between genotype and phenotype in three pediatric cases with IL10RA mutations and very early-onset inflammatory bowel disease

At a Glance

Key Highlights

• IL10RA mutations cause severe, progressive VEO-IBD with symptoms including refractory diarrhea, perianal lesions, oral ulcers, and growth delay
• Homozygous c.301 C > T(p.Arg101Trp) mutation is associated with a typical severe phenotype and very early symptom onset
• Compound heterozygous IL10RA mutations may present with distinct clinical spectra, but genotype–phenotype correlations require further study

Guideline-Based Recommendations

Diagnosis

• Consider VEO-IBD diagnosis in infants with persistent diarrhea, hematochezia, perianal lesions, and oral ulcers
• Perform whole-exome sequencing focusing on IL10RA mutations in suspected cases
• Conduct familial genetic testing for segregation analysis to determine inheritance patterns

Management

• Recognize poor response to conventional immunosuppressive therapies in IL10RA mutation-associated VEO-IBD
• Implement supportive care including nutritional support and infection control
• Consider early referral for hematopoietic stem cell transplantation as a potential curative approach (not detailed in article but implied by refractory disease)

Monitoring & Follow-up

• Regular clinical assessment of gastrointestinal symptoms and growth parameters
• Monitor inflammatory markers and serum IL-10 levels as indicators of disease activity
• Perform periodic endoscopic and histopathological evaluations to assess disease progression

Risks

• Severe intestinal inflammation leading to complications such as perianal abscesses, fistulas, and anal canal stenosis
• Delayed growth and development due to chronic inflammation and malnutrition
• Potential for refractory disease course with limited response to standard therapies

Patient & Prescribing Data

Three pediatric patients with VEO-IBD and confirmed pathogenic IL10RA mutations

Conservative treatments including antibiotics and amino acid-based formulas were ineffective in severe cases; genetic diagnosis informs prognosis and potential for targeted interventions

Clinical Best Practices

• Early genetic testing for IL10RA mutations in infants presenting with VEO-IBD symptoms
• Comprehensive clinical, laboratory, imaging, and histopathological evaluation to characterize disease severity
• Familial segregation analysis to confirm inheritance and support genetic counseling
• Multidisciplinary approach involving gastroenterology, immunology, genetics, and nutrition specialists

Related Resources & Content

• Very early-onset inflammatory bowel disease definitions and characteristics
• Role of IL10RA mutations in VEO-IBD pathogenesis
• American College of Medical Genetics and Genomics guidelines for variant classification